Search clinical trials for: LY450139

Total 56 results

Eli Lilly and Company

Completed

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

Alzheimer's Disease

Germany, Spain, Italy, United States, France, India, Chile, Poland, Australia, Belgium, South Africa, Israel, Sweden, Denmark, Canada, United Kingdom, Japan, Argentina, Finland
Eli Lilly and Company

Completed

A Study of Semagacestat for Alzheimer's Patients (Identity XT)

Alzheimer's Disease

United States, Germany, Chile, France, Spain, Australia, Israel, Italy, Poland, Canada, Sweden, South Africa, Finland, Japan
Eli Lilly and Company

Completed

Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (IDENTITY-2)

Alzheimer's Disease

United States, Italy, Mexico, France, Taiwan, Korea, Republic of, Japan, Germany, Bulgaria, China, Romania, Brazil, Canada, Ukraine, Russian Federation, Turkey, Hungary, Serbia
Eli Lilly and Company

Completed

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

Alzheimer Disease

United States
Eli Lilly and Company

Completed

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia (COMORBID©)

Benign Prostatic Hyperplasia | Erectile Dysfunction

United States, France, Italy, Greece, Mexico, Portugal, Canada, Germany, Russian Federation
Eli Lilly and Company

Completed

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

Benign Prostatic Hyperplasia

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction

Erectile Dysfunction

China
Eli Lilly and Company

Completed

Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
Eli Lilly and Company
ICOS Corporation

Completed

Tadalafil in Subjects With Mild to Moderate Hypertension

Hypertension

United States
Eli Lilly and Company
ICOS Corporation

Completed

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

Impotence

United States, Austria, France, Germany, Mexico
Eli Lilly and Company
ICOS Corporation

Completed

Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying

Gastroparesis

Canada
Eli Lilly and Company
ICOS Corporation

Completed

A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg

Erectile Dysfunction

United States
Eli Lilly and Company

Completed

A Study in Erectile Dysfunction

Erectile Dysfunction

United States
Eli Lilly and Company

Completed

A Study of Tadalafil After Radical Prostatectomy (REACTT)

Erectile Dysfunction

Germany, Belgium, Spain, United Kingdom, France, Italy, Netherlands, Canada, Poland, Switzerland
Eli Lilly and Company

Completed

Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia

Korea, Republic of, Japan
Eli Lilly and Company

Completed

A Study in Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States, Italy, Austria
Eli Lilly and Company

Completed

A Study of Tadalafil in Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

Germany
Eli Lilly and Company

Completed

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, France, Poland, Canada, United Kingdom
Eli Lilly and Company

Completed

A Bioavailability Study of LY2452473 and Tadalafil

Erectile Dysfunction

United States
Eli Lilly and Company
Nippon Shinyaku Co., Ltd.

Completed

A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).

Benign Prostatic Hyperplasia

Japan
Eli Lilly and Company

Completed

A Study in Erectile Dysfunction

Erectile Dysfunction

United States, Canada
Eli Lilly and Company

Completed

Effect of Tadalafil Once a Day in Men With Erectile Dysfunction

Erectile Dysfunction

Germany, Spain, Italy, Greece, Poland
Eli Lilly and Company
ICOS Corporation

Completed

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States, Greece, Portugal
Eli Lilly and Company
ICOS Corporation

Completed

Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction

Erectile Dysfunction | Impotence

Finland
Eli Lilly and Company
ICOS Corporation

Completed

Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury

Erectile Dysfunction | Spinal Cord Injuries

United States
Eli Lilly and Company
ICOS Corporation

Completed

To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections

Impotence

United States
Eli Lilly and Company
ICOS Corporation

Completed

Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects

Impotence

Sweden
Eli Lilly and Company
ICOS Corporation

Completed

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

Hypertension, Pulmonary

United States, Belgium, Canada, France, Germany, Ireland, Italy, Japan, Spain, United Kingdom
Eli Lilly and Company

Completed

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

Benign Prostatic Hyperplasia

Italy, United States, Germany, Mexico, Argentina
Eli Lilly and Company

Terminated

A Study of Tadalafil for Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne

Germany, United States, Spain, Belgium, France, Italy, Taiwan, Netherlands, Turkey, Korea, Republic of, Argentina, Canada, Japan, Puerto Rico, Russian Federation, United Kingdom
Eli Lilly and Company
ICOS Corporation

Completed

A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months

Erectile Dysfunction

United States
Eli Lilly and Company
ICOS Corporation

Completed

To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking

Impotence

United States
Eli Lilly and Company
ICOS Corporation

Completed

Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection

Impotence

Germany
Eli Lilly and Company
ICOS Corporation

Completed

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Eli Lilly and Company
ICOS Corporation

Completed

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Hypertension

France, United States, Italy
Eli Lilly and Company
ICOS Corporation

Completed

Determine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection

Impotence

China
Eli Lilly and Company
ICOS Corporation

Completed

Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection

Impotence

Japan
Eli Lilly and Company
ICOS Corporation

Completed

A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction

Erectile Dysfunction

United States
Eli Lilly and Company
ICOS Corporation

Completed

Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems (PILUTS)

Prostatic Hyperplasia | Prostate

United States
Eli Lilly and Company

Completed

Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

Benign Prostatic Hyperplasia

Japan
Eli Lilly and Company

Completed

A Study in Patients With Erectile Dysfunction

Erectile Dysfunction

Spain, Greece, France, United Kingdom, Portugal, Germany, Poland, Romania
Eli Lilly and Company

Completed

A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China

Erectile Dysfunction

China
Eli Lilly and Company
ICOS Corporation

Completed

Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection

Impotence

Korea, Republic of
Eli Lilly and Company
ICOS Corporation

Completed

Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection

Impotence

United Kingdom
Eli Lilly and Company
ICOS Corporation

Completed

Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations

Impotence

Brazil
Eli Lilly and Company

Completed

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Hypertension, Pulmonary

Spain, Poland, Belgium, Germany, Netherlands, United States, Japan, Brazil, Israel, Italy, Austria, Turkey, France, Mexico
Eli Lilly and Company

Completed

Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

Taiwan, Japan

Search clinical trials for: LY450139

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations